BR0107424A - Método para obtenção de estruturas antigênicas, estruturas antigênica, uso da mesma, formulação de vacina, e, uso da mesma - Google Patents

Método para obtenção de estruturas antigênicas, estruturas antigênica, uso da mesma, formulação de vacina, e, uso da mesma

Info

Publication number
BR0107424A
BR0107424A BR0107424-5A BR0107424A BR0107424A BR 0107424 A BR0107424 A BR 0107424A BR 0107424 A BR0107424 A BR 0107424A BR 0107424 A BR0107424 A BR 0107424A
Authority
BR
Brazil
Prior art keywords
structures
antigenic
antigenic structures
obtaining
formulation
Prior art date
Application number
BR0107424-5A
Other languages
English (en)
Inventor
Ricondo Luis Javier Cruz
Rubido Julio Cesar Aguilar
Perez Enrique Iglesias
Acosta Osvaldo Reyes
Perez Hilda Elisa Garay
Gonzalez Verena Lucila Muzio
Nieto Gerardo Enrique Guillen
Cano Carlos Duarte
Arias Eduardo Penton
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of BR0107424A publication Critical patent/BR0107424A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"MéTODO PARA OBTENçãO DE ESTRUTURAS ANTIGêNICAS, ESTRUTURA ANTIGêNICA, USO DA MESMA, FORMULAçãO DE VACINA, E, USO DA MESMA". A presente invenção está relacionada com um método para se obter estruturas antigênicas com alta reatividade cruzada, capazes de intensificar a resposta imune a antígenos peptídicos sistêmica e/ou mucosicamente administrados, e às estruturas químicas obtidas com dito método e as formulações obtidas a partir de ditas estruturas e seus usos. O método descreve a obtenção de novas estruturas dendriméricas a partir da seleção e síntese de dendrímeros, que são ligados subseq³entemente a moléculas portadoras. As estruturas resultantes podem ser usadas convenientemente adjuvadas ou em uma formulação na qual diversos antígenos deste tipo podem ser introduzidos, um efeito sinergístico acontecendo entre esses componentes em relação à reatividade cruzada e à imunogenicidade da resposta obtida. A preparação pode também conter estabilizadores e agentes conservantes. As estruturas antigênicas resultantes podem ser usadas na indústria farmacêutica como formulações de vacina para uso em seres humanos e animais e como parte de sistemas de diagnóstico.
BR0107424-5A 2000-11-03 2001-11-01 Método para obtenção de estruturas antigênicas, estruturas antigênica, uso da mesma, formulação de vacina, e, uso da mesma BR0107424A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2000024220000242A CU23011A1 (es) 2000-11-03 2000-11-03 Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
PCT/CU2001/000007 WO2002036160A2 (es) 2000-11-03 2001-11-01 Método de obtención de estructuras antigénicas que potencian la reactividad cruzada específica

Publications (1)

Publication Number Publication Date
BR0107424A true BR0107424A (pt) 2002-10-15

Family

ID=5459562

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107424-5A BR0107424A (pt) 2000-11-03 2001-11-01 Método para obtenção de estruturas antigênicas, estruturas antigênica, uso da mesma, formulação de vacina, e, uso da mesma

Country Status (15)

Country Link
EP (1) EP1334727A2 (pt)
JP (1) JP4099059B2 (pt)
KR (1) KR100887591B1 (pt)
CN (1) CN100387616C (pt)
AR (1) AR031182A1 (pt)
AU (2) AU1493802A (pt)
BR (1) BR0107424A (pt)
CA (1) CA2427539A1 (pt)
CU (1) CU23011A1 (pt)
EA (1) EA005313B1 (pt)
HK (1) HK1058154A1 (pt)
MX (1) MXPA03003849A (pt)
MY (1) MY137709A (pt)
WO (1) WO2002036160A2 (pt)
ZA (1) ZA200205236B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
DE102007002726A1 (de) * 2007-01-18 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Neue Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
PL230663B1 (pl) 2015-01-15 2018-11-30 Univ Gdanski Szczepionka, sposob jej otrzymywania, wyizolowane chimeryczne bialko, wektor ekspresyjny, zestaw zawierajacy szczepionke oraz kompozycja do zastosowania w profilaktyce zakazen powodowanych przez HCV i/lub HBV

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3786000T3 (de) * 1986-08-18 1997-08-21 Dow Chemical Co Conjugate dichter Sterne.
CU22629A1 (es) * 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal

Also Published As

Publication number Publication date
CN100387616C (zh) 2008-05-14
KR20020080360A (ko) 2002-10-23
WO2002036160A2 (es) 2002-05-10
AU1493802A (en) 2002-05-15
ZA200205236B (en) 2003-09-29
AR031182A1 (es) 2003-09-10
MY137709A (en) 2009-02-27
WO2002036160A3 (es) 2003-05-30
EP1334727A2 (en) 2003-08-13
CN1446094A (zh) 2003-10-01
JP2004513897A (ja) 2004-05-13
JP4099059B2 (ja) 2008-06-11
AU2002214938B2 (en) 2006-04-13
EA005313B1 (ru) 2004-12-30
EA200300535A1 (ru) 2003-10-30
MXPA03003849A (es) 2004-10-15
KR100887591B1 (ko) 2009-03-10
HK1058154A1 (en) 2004-05-07
CA2427539A1 (en) 2003-05-01
CU23011A1 (es) 2004-12-17

Similar Documents

Publication Publication Date Title
ES2139879T5 (es) Adyuvante de la mucosa no toxico.
CA2201611C (en) Saponin preparations and use thereof in iscoms
ES2258108T3 (es) Vacunas con respuesta inmune mejorada y procedimientos de preparacion de las mismas.
Norgard et al. Dermal inflammation elicited by synthetic analogs of Treponema pallidum and Borrelia burgdorferi lipoproteins
BRPI0411505A (pt) uso de um composto, método para modular a resposta imune de um indivìduo, composição farmacêutica, vacina, complexo, e, kit para a captura de uma molécula biologicamente ativa
AR035586A1 (es) Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn
BR0316402A (pt) vesìcula fusogênica, métodos para preparar uma vesìcula fusogênica encapsulante, e para encapsular pelo menos uma substáncia terapêutica ou imunologicamente ativa em uma vesìcula fusogênica, uso de uma vesìcula fusogênica, e, formulação farmacêutica
JPS63501078A (ja) 免疫原性複合体の製造法
JP2004002463A (ja) インターロイキン含有安定ワクチン組成物
JPH07509733A (ja) 代謝可能な油を含む油中水型のワクチン用液体エマルジョン
AU3338495A (en) Quinoa saponin compositions and methods of use
BR0207016A (pt) Fator neurotrófico derivado de cérebro humano modificado (bdnf) com imunogenicidade reduzida
BR0010682A (pt) Novas composições
BR0107424A (pt) Método para obtenção de estruturas antigênicas, estruturas antigênica, uso da mesma, formulação de vacina, e, uso da mesma
ES2375267T3 (es) Combinación de lípidos y de óxido nitroso como adyuvante para potenciar de la eficacia de vacunas.
BR112012022059B1 (pt) Vacina de mucosa produtora de uma iga de mucosa antígenoespecífica e igg do sangue e método para produzir uma vacina de mucosa
DE69031351D1 (de) Zubereitungen und behandlungen von pneumonia in tieren
ES2388684T3 (es) Adyuvantes de vacunas
ES2279650T3 (es) Dispositivo de entrega para una composicion de una sustancia farmaceuticamente activa.
PT680765E (pt) Vacina para estirpe não tipável de haemophilus influenzae.
Zemelman et al. Host response to Escherichia coli heat-labile enterotoxin via two microvillus membrane receptors in the rat intestine
Edelman et al. Summary of an international symposium on potentiation of the immune response to vaccines
ES2364595T3 (es) Preparación externa para la piel en forma de emulsión de agua en aceite que comprende ceramida.
ES2742325T3 (es) Composiciones de vacuna novedosas que comprenden oligonucleótidos inmunoestimulantes
BR0115859A (pt) Método de obtenção de estruturas antigênicas agregadas de alta imunogenicidade, estrutura antigênica agregada, formulação de vacina e usos de uma estrutura antigênica e de formulações de vacina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.